We studied whether the induction of autologous graftversus-host disease (GVHD) has an antileukemic effect and consequently increases the survival of patients undergoing autologous peripheral blood stem cell transplantation (PBSCT). In all, 22 acute myeloid leukemia patients with favorable and intermediate cytogenetic risk, in their first complete remission, were administered cyclosporine c.i.v. from day 0 to day þ 28 at a dose of 3.0 mg/kg per day and interferon-c (IFN-c) at 0.025 mg/m 2 s.c. every other day from day þ 14 to day þ 42 following autologous PBSCT. Natural-killer (NK)-cell activity assays and skin biopsies were performed. Successful engraftment was achieved in all patients at a median of 13 days without significant additional toxicity. Histologically confirmed cutaneous GVHD developed in 12 patients, and NK-cell activity was significantly augmented after autologous PBSCT in those patients (P ¼ 0.03). After a median follow-up duration of 37.7 months (range, 7.3-72.8), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 64.4 and 73.1%, respectively, without significant correlation with GVHD status or augmentation of NK-cell activity. These data suggest that the administration of cyclosporine and IFN-c following autologous PBSCT improves OS and DFS, which may be attributable to the antileukemic effect, although no difference in survival could be demonstrated between cutaneous GVHD-positive and -negative groups. Bone Marrow Transplantation (2003) 32, 889-895. doi:10.1038/sj.bmt.1704251 Keywords: autologous GVHD; autologous stem cell transplantation; interferon-g; cyclosporine; natural-killercell activity; acute myeloid leukemia Clinically beneficial antitumor effects of graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (BMT) have been reported previously, despite the fact that GVHD is associated with increased morbidity and mortality.
autologous GVHD; autologous stem cell transplantation; interferon-g; cyclosporine; natural-killercell activity; acute myeloid leukemia Clinically beneficial antitumor effects of graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (BMT) have been reported previously, despite the fact that GVHD is associated with increased morbidity and mortality. 1 Unfortunately, only 25% of patients have a suitable donor for allogeneic BMT and the remaining patients are eligible only for autologous stem cell transplantation (SCT) or unrelated-donor BMT. Although unrelated or mismatched-related BMT are associated with potent antitumor effects, many patients still lack a suitable donor or are not suitable candidates. The lack of a graftversus-tumor effect associated with GVHD may at least partly account for the higher relapse rate in autologous SCT patients. 2 On the basis of findings that the relapse rate after allogeneic SCT is remarkably lower in patients with GVHD compared with patients who do not develop this syndrome, 1, 3, 4 the induction of autologous GVHD is one potential approach with which to improve the outcome for autologous SCT. Autologous GVHD can be induced by the administration of cyclosporine A (CsA) for a short period following autologous SCT. [5] [6] [7] This autoaggression syndrome shares a similar cutaneous pathology with acute GVHD after allogeneic SCT, even though autologous GVHD is milder, involves only the skin, and is self-limiting. Several initial clinical trials in patients with acute myeloid leukemia (AML) and non-Hodgkin's lymphoma suggest that the induction of autologous GVHD can reduce the rate of relapse. [8] [9] [10] Analysis of the effector mechanisms involved in autologous GVHD reveals promiscuous recognition of the major histocompatibility complex (MHC) class II determinants by CD8 þ T cells. 11, 12 Critical for the induction of this autoaggression syndrome is the elimination of the peripheral regulatory mechanism that controls autoreactive T cells. 13 The elimination of peripheral immunoregulatory mature T cells by a preparative regimen provides a permissive environment for the autoreactive T cells to manifest autoaggression. Moreover, the antitumor effects of CsA-induced autologous GVHD can be enhanced by the administration of interferon-g (IFN-g). This is thought to be principally due to the upregulation of the MHC class II target antigen on the tumor cells. 14, 15 The effect of IFN-g on potentiating CsA-induced autologous GVHD in autologous SCT has already been examined in breast cancer and hematological malignancies, and showed an increased severity of GVHD. 10, 16, 17 Natural killer (NK) cells have also been implicated in graft-versus-leukemia (GVL) effects in murine and human SCT and are involved in GVL effects in murine and human allogeneic BMT, independent of GVHD, with a reduced rate of leukemia relapse. 18, 19 Other studies in mice and humans have demonstrated that NK cells have an important role in the development of murine syngeneic GVHD (SGVHD), and autologous GVHD in human autologous SCT. 17, 20 Our aim in this study was to determine whether the induction of autologous GVHD by the administration of CsA and IFN-g has an antileukemic effect and consequently increases survival rates in patients who undergo autologous peripheral blood stem cell transplantation (PBSCT) for the treatment of AML in the first complete remission (CR). Furthermore, we evaluated the correlation between autologous GVHD and NK-cell activity, and their influence on the GVL effect.
Patients and methods

Patients
This study was designed as a single-arm, nonrandomized pilot study. Patients eligible for the study were between 16 and 65 years old, with AML, in favorable, intermediate, or unknown risk categories in terms of cytogenetic abnormalities. 21, 22 Among the patients who attained the first CR following standard induction therapy, all patients with favorable risk cytogenetics and patients who had intermediate or unknown risk cytogenetics, but did not have a histocompatible sibling donor for allogeneic BMT, were eligible for inclusion. All patients were required to have normal renal, cardiac, pulmonary, and hematopoietic reserves as well as an ECOG performance status of zero to one. This trial was approved by the Institutional Review Board at the Samsung Medical Center. All patients or their guardians were required to provide informed consent before enrolment in this study. 26 h as a single dose followed by cyclophosphamide (CY) at 60 mg/kg per day i.v. over 2 h for 3 days, followed by total body irradiation (TBI) at 300 cGy per day for the next 3 days. CY þ TBI consisted of CY at 60 mg/kg per day i.v. over 2 h for 2 days, followed by TBI 300 at cGy per day for 4 days. BU þ CY consisted of busulfan (BU) at 1 mg/kg per oral dose or 0.8 mg/kg per i.v. dose every 6 h for 16 doses (4 days), followed by CY at 60 mg/kg per day i.v. over 2 h for 2 days. To calculate dose, ideal body weight or actual body weight, whichever was less, was used. Intensive i.v. hydration was applied to prevent hemorrhagic cystitis. After completion of the conditioning regimen, cryopreserved stem cells were thawed at 371C in a water bath and infused through a Hickman catheter using a standard blood administration set without a filter. Patients were pre medicated with antihistamines and steroids to minimize the effects of dimethylsulfoxide-mediated histamine release.
Induction and consolidation therapy
Administration of cyclosporine and IFN-g
CsA (Novartis, Basel, Switzerland) was administered as a c.i.v. infusion beginning on the day of autologous PBSC infusion, at a dose of 3.0 mg/kg (ideal body weight) over 24 h. This was switched to an oral formula if the patient could tolerate oral medications, and was continued for 28 days (days 0-28). The dose was adjusted to maintain a whole-blood level of 200-300 ng/ml. Blood CsA levels were checked at least twice a week. If the patient's serum creatinine level rose above 2.0 mg%, CsA treatment was stopped, and recommenced when renal function had improved, as shown by the serum creatinine level returning to normal.
IFN-g (LGCI, Seoul, Korea) was administered at 0.025 mg/m 2 every other day by subcutaneous injection from days 14 to 42.
Evaluation of GVHD, engraftment, and toxicity
All patients were observed for the development of GVHD or any untoward effects of CsA and IFN-g. Complete blood counts and blood chemistry were evaluated at least once a week and patients were assessed for any evidence of rash, jaundice, or diarrhea up until day 56. All patients had a skin biopsy performed on days 21 and 42, and further biopsies were performed if a skin rash developed. Each biopsy specimen was examined by a pathologist and graded according to standard published criteria. 23, 24 Histological grades 1-4 GVHD was defined as a positive result for histological GVHD, whereas no histological evidence of GVHD or suspicious GVHD was deemed to be a negative Auto-PBSCT with induction of auto-GVHD in AML result. Peripheral blood samples collected to assay NK-cell activity were drawn on the day before the conditioning treatment, and after PBSCT on days 21, 42, 100, 180, and 365. The time to white-blood-cell (WBC) engraftment was defined as the number of days from the day of PBSC infusion until the absolute neutrophil count (ANC) reached levels above 500 cells/ml for 3 consecutive days. The time to platelet engraftment was defined as the number of days from the day of PBSC infusion until the platelet count was maintained above 2 Â 10 4 platelets/ml on 7 consecutive days, without platelet transfusion. Nonhematological toxicity was measured according to NCI common toxicity criteria.
NK-cell activity assay
NK-cell activity was measured as previously described by Yoon et al 25 with appropriate modifications. Lymphocytes prepared from human peripheral blood by density-gradient separation using Lymphoprept (Nycomed Pharma AS, Oslo, Norway) served as effector cells (E). Log-phase K562 cells, a human chronic myelogenous leukemia cell line sensitive to NK-cell killing, were labeled with Na 2 51 CrO 4 and used as target cells (T). Labeled K562 cells, 100 ml (1 Â 10 4 cells) and 100 ml of the selected concentration of effector cell (E:T ¼ 25:1 or 50:1), were dispensed in a U-bottomed 96-well microtiter plate. After 4 h of incubation at 371C in a humidified 5% CO 2 incubator, the plates were centrifuged at 400 g for 10 min, and 100 ml of supernatant was removed. Radioactivity levels were assessed in a Wallac 1470 Wizardt gamma counter (Finland). Spontaneous release (SR) and total release (TR) were measured in the supernatants of target cells incubated with either culture medium or 1 N HCl. Percentage NK-cell activity was calculated by
Augmentation of NK-cell activity was defined by two criteria: when % NK-cell activity at post PBSCT was double that at pre transplantation and when the absolute value of % NK-cell activity on post transplantation day 21 or 42 was greater than 50%.
Statistical analysis
The association between the induction of GVHD and each of the variables of interest was measured using w 2 or Fisher's exact tests. Disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and the differences between patients who developed autologous GVHD and those who did not were evaluated by a log-rank test. For continuous variables, Cox regression analysis was used to investigate the association between DFS, OS, and each of the variables examined. All reported P-values are two-sided, and statistical significance was defined as Po0.05.
Results
Patient characteristics
Between May 1998 and October 2002, 22 patients were enrolled in this study at the Samsung Medical Center. Their characteristics are shown in Table 1 . Nine men and 13 women, with a median age of 34 years (range, 16-55 years), participated in the study. All the patients were diagnosed with AML, and had attained first CR following standard induction therapy. Patients achieving a CR received two courses of consolidation therapy consisting of idarubicin and cytarabine. The median duration from initial diagnosis to the attainment of CR and autologous PBSCT were 30 days (range, 21-46 days) and 142 days (range, 106-200 days), respectively and the median interval between CR 22 
Induction of GVHD
One of the patients treated with CsA and IFN-g developed acute clinical GVHD with a skin rash on the soles and palms, which was easily manageable. Histologically confirmed cutaneous GVHD was observed in 12 of 22 patients on the basis of skin biopsies performed on days 21 and 42 after autologous PBSCT. No patients attained grade 3 or 4 disease; grade 2 disease was observed in three patients and grade 1 disease occurred in nine patients. Of the 18 patients who received TBI, 10 developed cutaneous autologous GVHD. No other factors significantly influenced the development of GVHD.
NK-cell activity
The median value for the initial base-line NK-cell activity was 21.3%, and this tended to peak at days 21 and 42, with median values of 49.4 and 51.1%, respectively. Augmentation of NK-cell activity was observed in 12 of 22 patients, and eight of these 12 patients developed GVHD. NK-cell activity was analyzed and compared with patients' GVHD status. Interestingly, the NK-cell activity of patients who developed cutaneous GVHD was significantly augmented after PBSCT compared with that of patients without cutaneous GVHD (P ¼ 0.03).
Engraftment and toxicity
There were no treatment-related deaths in this study. One major toxic effect of IFN-g was its suppressive effect on marrow engraftment. Nevertheless, successful engraftments were achieved in all patients, with ANC recovery above 500 cells/ml at a median of 11 days (range, 9-37 days) and platelet counts exceeding 2 Â 10 4 platelets/ml at a median of 13 days (range, 9-187 days). In terms of nonhematological toxicity, grade 1 or 2 gastrointestinal, hepatic, and renal toxicities were observed, and fever not caused by any documented infection also developed, as did hypertension. However, no grade 3 or 4 toxicity was observed. It was not clear whether these toxicities were solely ascribable to IFN-g and CsA, as this was difficult to determine.
Survival
During the median follow-up duration of 37.7 months (range, 7.3-72.8 months), six of 22 (27.3%) patients relapsed and four of them died. The 3-year DFS and OS rates for all patients were 64.4 and 73.1%, respectively.
Cutaneous manifestation of GVHD induced by CsA and IFN-g following autologous PBSCT did not correlate significantly with improvement in DFS or OS rates when these survivals were analyzed and divided according to their GVHD status ( Figure 1 ) (P ¼ 0.35 and 0.42, respectively). Although augmentation of NK-cell activity correlated significantly with the development of cutaneous GVHD (P ¼ 0.03), it failed to correlate with a significant improvement in DFS or OS (P ¼ 0.31 and 0.33, respectively) (Figure 2 ).
Discussion
In this study, cutaneous GVHD was induced by the administration of CsA and IFN-g following autologous PBSCT, without significant additional toxicity or impairment of engraftment. OS and DFS also appeared to Auto-PBSCT with induction of auto-GVHD in AML improve compared with those of autologous BMT or chemotherapy alone in AML patients with similar cytogenetic risk groups in the previous data. 21, 22 In several clinical trials, IFN-g was given with CsA after autologous transplantation with tolerable side effects and toxicities.
9,10,17 Vogelsang et al 9 reported that four of their 19 patients with various hematological malignancies developed clinical GVHD, with encouraging survival benefits, in an autologous BMT trial using CsA and IFN-g. A previous study using the same drug combination as used in the present study found that 56% of 36 patients with breast cancer who received autologous PBSCT developed cutaneous GVHD. 16 Elimination of peripheral immunoregulatory mature T cells by the preparative regimen provides a permissive environment for the activation of syngeneic/ autologous GVHD effector T cells that have escaped clonal deletion in the thymus through the effects of cyclosporine. 13 In our trial, cutaneous GVHD developed in 50% of the 18 patients who received TBI as a conditioning regimen. This result is similar to those of the previous studies described above, in which the incidence of autologous GVHD in patients receiving TBI during PBSCT was up to 64%, whereas those not receiving TBI and undergoing transplantation with unmanipulated PBSCs failed to develop GVHD. 10 Whether a TBI-containing regimen is more effective for the induction of autologous GVHD in PBSCT than regimens not containing TBI remains to be determined.
A GVL effect is produced in allogeneic transplants even when clinically significant GVHD is not present. Previous several data suggested that GVL effect might be at least partially separable from GVHD. 18, 19, [26] [27] [28] Moreover, analysis of clinical data from the International Bone Marrow Transplant Registry indicated that AML patients receiving transplants from an identical twin had an increased probability of relapse (relative risk 2.58, P ¼ 0.008) compared with allograft recipients without GVHD. This result supported an antileukemia effect of allografts that was independent of GVHD. 26 Several studies on autologous PBSCT have also revealed a GVL effect with a reduced relapse rate or a improved survival rate without significant correlation with GVHD. 7, 9, 17 The data presented here suggest that the administration of CsA and IFN-g following autologous PBSCT improves OS and DFS, which may be attributable to the antileukemic effect. When patients in this study were divided into two groups according to their cutaneous GVHD status, however, no significant differences could be demonstrated with regard to survival outcomes. Therefore, from the results of this trial, it can be deduced that even subclinical autologous GVHD contributed to the GVL effect and subsequently to the survival gain. However, the number of patients recruited in this study was still too small to show differences between the possible outcomes of patients who developed GVHD and those who did not.
In a murine model, NK cells were involved in GVL effects independent of GVHD. 18 Jiang et al 19 reported that NK-cell recovery correlated more closely with a GVL effect than with a GVH effect in human patients with CML who received allogeneic BMT, with a reduced leukemia relapse rate. These findings support a more central role for cytokines in the GVHD process, operating independent of immune recovery as measured by subset counts and NK-cell function. On the other hand, Flanagan et al 20 demonstrated a role for IL-12 and NK cells in the effector phase of murine SGVHD. In that study, depletion of NK cells in vivo inhibited the disease process, whereas depletion of T cells did not inhibit SGVHD. The secretion of IL-12 (by macrophages) can activate the effector cell population (NK cells). The effector cells can then become cytolytic and directly cause tissue damage. They also secrete IFN-g, which would feed back and enhance the secretion of IL-12 and other proinflammatory mediators, thereby amplifying the response. In a previously reported study using autologous PBSCT in advanced breast cancer, NK-cell activity was also increased in patients who developed cutaneous grade II autologous GVHD. 17 In accordance with those results, our study revealed increased NK-cell activity, which correlated significantly with the development of autologous cutaneous GVHD. There was a trend towards better OS and DFS in patients with augmented NK-cell activity, but this was not statistically significant. A recent study of autologous BMT demonstrated that IL-10 may play an unexpected, but critical, role in autologous GVHD, and could be used to enhance the GVL effect after transplantation. 29 Baron et al 7 demonstrated with multivariate analysis that the strongest predictive factor for the development of autologous GVHD is a diagnosis of myeloid malignancies, not a diagnosis of lymphoid malignancies or solid tumors. Furthermore, Linker 30 suggested that AML patients in first CR with favorable-risk cytogenetics and those with intermediate-risk cytogenetics who had no suitable HLAidentical donor for allogeneic BMT benefit from autologous PBSCT. Therefore, a major point of our study was to demonstrate the influence of autologous GVHD on survival in the homogeneous patient population with AML in first CR.
In conclusion, cutaneous GVHD can be induced by the administration of CsA and IFN-g following autologous PBSCT in first CR of AML, with augmentation of NK-cell activity. The data presented here suggest that the administration of CsA and IFN-g following autologous PBSCT improves OS and DFS, which may be attributable to the antileukemic effect, although no significant differences could be demonstrated between cutaneous GVHD positive and negative groups with regard to survival outcomes.
